NASDAQ:ARGX - Nasdaq - US04016X1019 - ADR - Currency: USD
Taking everything into account, ARGX scores 5 out of 10 in our fundamental rating. ARGX was compared to 556 industry peers in the Biotechnology industry. While ARGX seems to be doing ok healthwise, there are quite some concerns on its profitability. ARGX is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 13.42% | ||
ROE | 15.14% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | 38.01% | ||
GM | 89.65% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.01 | ||
Debt/FCF | N/A | ||
Altman-Z | 29.3 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 7.29 | ||
Quick Ratio | 6.68 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 94.52 | ||
Fwd PE | 24.87 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | 25756.48 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
543.48
-1.63 (-0.3%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 94.52 | ||
Fwd PE | 24.87 | ||
P/S | 15.15 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 6.04 | ||
P/tB | 6.24 | ||
EV/EBITDA | 25756.48 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 13.42% | ||
ROE | 15.14% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | 38.01% | ||
GM | 89.65% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.01 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | 29.94 | ||
Cap/Depr | 389.69% | ||
Cap/Sales | 3.12% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 7.29 | ||
Quick Ratio | 6.68 | ||
Altman-Z | 29.3 |